Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis

Table 2 Treatment patterns for anti-TNFα biologic therapy in patients with PsA for the 3-year follow-up

	Patients With Only First-line Anti-TNFα Biologic Therapy (n = 881)^a	Patients With Second-line Anti-TNFα Biologic Therapy (n = 72)^a	Patients with Third-line or Greater of Anti-TNFα Biologic Therapy (n = 37)^a
Persistent use of anti-TNFα biologic therapy (days), mean (SD)^b
First-line	522.3 (418.9)	348.5 (308.7)	325.2 (239.9)
Second-line	N/A	447.3 (327.6)	126.8 (197.9)
Third-line or greater	N/A	N/A	251.6 (305.2)
Time to switch anti-TNFα biologic therapy(days), mean (SD)^c
First-line	N/A	349.5 (308.7)	326.2 (239.9)
Second-line	N/A	N/A	127.8 (197.9)
Third-line or greater	N/A	N/A	40.2 (49.8)
Time to first modification of anti-TNFα biologic therapy (days), mean (SD)^d,e
First-line	119.4 (208.7)	58.4 (102.7)	219.8 (295.4)
Second-line	N/A	189.5 (226.0)	76.1 (238.9)
Third-line or greater	N/A	N/A	24.3 (33.3)
Time from first modification of anti-TNFα biologic therapy to switch (days), mean (SD)^f
First-line	N/A	385.3 (277.1)	143.5 (199.0)
Second-line	N/A	N/A	38.1 (53.7)
Third-line or greater	N/A	N/A	42.0 (65.6)

PsA psoriatic arthritis, N/A not available, SD standard deviation, TNFα tumor necrosis factor-α
^aAnti-TNFα biologic therapy refers to the following anti-TNFα agents: etanercept, adalimumab, infliximab, and golimumab
^bPersistent use was defined as time from initiation of the line of treatment to discontinuation (a gap in treatment of >60 days) of the line of treatment or switch to the next line of treatment (whichever came first)
^cTime to switch is defined as time from initiation of the line of anti-TNFα biologic treatment to switch to the next line of anti-TNFα biologic treatment
^dTime to first modification of anti-TNFα biologic therapy was defined as time from initiation of the line of anti-TNFα biologic treatment to first modification on that line of treatment
^eModification of anti-TNFα biologic therapy included: biologic dose increase or dose decrease, DMARD added, changed, removed, or DMARD dose increase/decrease; Benchmark DMARD to identify first-line DMARD change: most recent DMARD in 60-day prior to index biologics; Benchmark DMARD to identify second-/third-line DMARD change: most recent DMARD in the previous line
^fTime from first modification of anti-TNFα biologic therapy to switch was defined as time from first modification on the line of anti-TNFα biologic treatment to switch to the next line of treatment

ISSN: 1471-2474